Ception Therapeutics - Top 20 VC deals of 2007

Company: Ception Therapeutics
Based: Malvern, PA
Amount: $77.7M
Round: Third
Investors: Aperture Venture Partners, Essex Woodlands Health Ventures, Greenlight Capital, Individuals, Investor Growth Capital, Lumira Capital Corporation, New Science Ventures, Undisclosed Investor

Scoop: Ception's pipeline includes a late-stage biologic agent (Anti-IL5 MAb) in clinical development for eosinophilic esophagitis and other inflammatory conditions. The company is also working on an oral Anti-TNF drug, an anti-infective program and a novel anti-thrombotic program.

More News:
Ception adds $14.7M to big third round. Report
Ception Therapeutics pockets $63M in third round. Report

Ception Therapeutics - Top 20 VC deals of 2007
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.